Analystreport

Allogene Therapeutics, Inc. (NASDAQ: ALLO) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report